Boehringer Ingelheim International GmbH
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$153.4M
Doctors Paid
1,050
Transactions
63,704
2024 Total
$40.0M
Payment Breakdown by Category
Research$130.3M (84.9%)
Consulting$11.6M (7.6%)
Travel$3.5M (2.3%)
Food & Beverage$126,163 (0.1%)
Royalty/License$612.72 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $130.3M | 52,892 | 84.9% |
| Consulting Fee | $11.6M | 3,356 | 7.6% |
| Grant | $4.8M | 33 | 3.1% |
| Travel and Lodging | $3.5M | 1,992 | 2.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3.1M | 3,371 | 2.0% |
| Food and Beverage | $126,163 | 2,059 | 0.1% |
| Royalty or License | $612.72 | 1 | 0.0% |
Payments by Type
Research
$130.3M
52,892 transactions
General
$23.1M
10,812 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Empagliflozin and heart failure (HFpEF) | $9.8M | 2 | 20,865 |
| BI 456906 in NAFLD | $9.7M | 0 | 84 |
| EMPA-KIDNEY | $8.0M | 0 | 1,515 |
| Comparative study in Psoriasis | $5.6M | 0 | 2,684 |
| Bioequivalence BI695501 50mg mL vs 100mg mL | $5.4M | 0 | 6 |
| MRD/PoCP study in NFLD (12 wks) | $5.3M | 0 | 28 |
| Phase II DRF study of NR2B modulation in MDD | $5.2M | 0 | 40 |
| BI754111 & BI754091/BI75411 combination | $4.8M | 0 | 962 |
| Empagliflozin and Heart failure (HFrEF) | $4.8M | 0 | 9,136 |
| BI 690517+Empa - Placebo+Empa in patients w. HF (LVEF) | $3.1M | 0 | 177 |
| ZAN-BPD Content Validity Study | $2.8M | 0 | 56 |
| CARMELINA | $2.8M | 1 | 389 |
| safety and efficacy linagliptin vs SU | $2.7M | 0 | 523 |
| Decentralized Clinical Trial in MDD | $2.6M | 0 | 37 |
| Ph1 mono/combi+PD1 in advanced tumours | $2.3M | 0 | 308 |
| BAML-16-001-S2/BI 836858 with 5-Aza | $2.3M | 0 | 323 |
| BI 754091 first-in-man dose escalation | $2.2M | 0 | 747 |
| Empagliflozin for prevention of HHF and death afte | $2.2M | 0 | 219 |
| Obesity Long term safety in patients with CV risk | $2.2M | 0 | 339 |
| Phase 1 dose escalation study of BI 765049 mono / combi | $2.1M | 0 | 105 |
| PD1 + longitudinal study | $2.1M | 0 | 995 |
| Empagliflozin for prevention of HHF and death after an AMI | $2.1M | 0 | 458 |
| Efficacy and safety in colorectal cancer | $2.0M | 0 | 948 |
| PD1 longitudinal study | $2.0M | 0 | 75 |
| Research Collaboration | $1.8M | 0 | 18 |
| PD1 & longitudinal study | $1.8M | 0 | 17 |
| EMPA KIDNEY | $1.7M | 0 | 85 |
| Slope Estimation and Homogeneity Study | $1.3M | 0 | 203 |
| Evaluation of photosafety of BI 730357 | $1.3M | 0 | 28 |
| BI 695501 in Plaque Psoriasis Efficacy | $1.1M | 0 | 1,208 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Javed Butler, Md, Mph, MD, MPH | Cardiovascular Disease | Jackson, MS | $691,832 | $0 |
| Dr. Peter Carson, M.d, M.D | Specialist | Washington, DC | $524,179 | $0 |
| Dr. Sanjay Kaul, M.d, M.D | Specialist | Los Angeles, CA | $453,831 | $0 |
| John Teerlink, M.d, M.D | Internal Medicine | San Francisco, CA | $414,356 | $0 |
| Dr. Inderjit Anand, Md, Frcp, D Phil, Fa, MD, FRCP, D PHIL, FA | Cardiovascular Disease | Minneapolis, MN | $393,592 | $0 |
| Dr. Alan Miller, M.d, M.D | Internal Medicine | Jacksonville, FL | $267,713 | $0 |
| Dr. Elizabeth Volkmann, Md, MD | Internal Medicine | Los Angeles, CA | $218,764 | $0 |
| Darren Mcguire, Md, MD | Cardiovascular Disease | Dallas, TX | $198,953 | $0 |
| Dr. Julio Rosenstock, M.d, M.D | Endocrinology, Diabetes & Metabolism | Dallas, TX | $192,429 | $0 |
| Silvio Inzucchi, Md, MD | Endocrinology, Diabetes & Metabolism | New Haven, CT | $161,814 | $0 |
| Maria Rosa Costanzo, Md, MD | Advanced Heart Failure and Transplant Cardiology | Naperville, IL | $156,111 | $0 |
| Prof. Toby Maher, Md, MD | Pulmonary Disease | Los Angeles, CA | $155,303 | $0 |
| Kevin Flaherty, Md, MD | Internal Medicine | Ann Arbor, MI | $126,222 | $0 |
| Dr. James Januzzi, Md, MD | Internal Medicine | Boston, MA | $120,434 | $0 |
| Charles Wykoff, Md, Phd, MD, PHD | Retina Specialist | Bellaire, TX | $120,354 | $0 |
| Biykem Bozkurt, M.d, M.D | Internal Medicine | Houston, TX | $110,155 | $0 |
| Rajiv Agarwal, M.d, M.D | Nephrology | Indianapolis, IN | $108,579 | $0 |
| Dr. Shervin Assassi, M.d, M.D | Rheumatology | Houston, TX | $108,227 | $0 |
| Antonio Anzueto, Md, MD | Pulmonary Disease | San Antonio, TX | $106,817 | $0 |
| Bruce Strober, M.d, M.D | Dermatology | Cromwell, CT | $105,644 | $0 |
| Susan Bressler, M.d, M.D | Ophthalmology | Lutherville, MD | $103,632 | $0 |
| Dr. Justis Ehlers, M.d, M.D | Ophthalmology | Cleveland, OH | $100,748 | $0 |
| Bruce Rubin, Md, Mengr, Mba, MD, MENGR, MBA | Pediatric Pulmonology | Richmond, VA | $100,337 | $0 |
| Dr. Mark Lebwohl | Dermatology | New York, NY | $94,317 | $0 |
| Dr. Elaine Hylek, M.d, M.D | Internal Medicine | Boston, MA | $93,491 | $0 |
Ad
Top Products
- JARDIANCE $36.6M
- TRADJENTA $7.5M
Associated Products (2)
- GLYXAMBI $193,688
- NINTEDANIB $37,081
Payment Categories
- Food & Beverage $126,163
- Consulting $11.6M
- Travel & Lodging $3.5M
- Research $130.3M
- Royalties $612.72
About Boehringer Ingelheim International GmbH
Boehringer Ingelheim International GmbH has made $153.4M in payments to 1,050 healthcare providers, recorded across 63,704 transactions in the CMS Open Payments database. In 2024, the company paid $40.0M. The top product by payment volume is JARDIANCE ($36.6M).
Payments were distributed across 94 medical specialties. The top specialty by payment amount is Internal Medicine ($3.3M to 184 doctors).
Payment categories include: Food & Beverage ($126,163), Consulting ($11.6M), Research ($130.3M), Travel & Lodging ($3.5M), Royalties ($612.72).
Boehringer Ingelheim International GmbH is associated with 2 products in the CMS Open Payments database.